Press releases

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...

Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...

Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion...

DEINOVE immediately strengthens its cash position by €1 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses...

For the second year in a row, DEINOVE has called on Société Générale Factoring (SGF) to pre-finance its R&D Tax Credit receivable...

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...

The 2019 financial results are postponed to April 29, 2020. At this stage, the other dates remain unchanged. DEINOVE (Euronext Growth Paris...